Treatment of Mild to Moderate Plaque Psoriasis with Pimecrolimus, Clobetasol, or Calcipotriol Cream: A comparative study
DOI:
https://doi.org/10.32007/jfacmedbagdad.581194Keywords:
psoriasis; pimecrolimus; clobetasol; calcipotriol; efficacy; safety.Abstract
Background: a number of studies have shown that application of topical calcineurin inhibitors is effective for a broad spectrum of inflammatory skin disorders.
Objective: to compare the efficacy and safety of 1% of pimecrolimus cream versus 0.05% of clobetasol cream and 0.005% of calcipotriol cream in psoriatic patients.
Patients and methods: adults on stable plaque psoriasis were randomized to three treatment groups (pimecrolimus, clobetasol, and calcipotriol group). The criteria of inclusion involve affected BSA of ≤10%, with a local psoriasis severity index (LPSI) score of ≥5. The main assessment of clinical efficacy was the percent changes in LPSI. The quantitative determination of cytokine levels (IL -6, s IL-2R, TNF-α), skin biopsies, and creams safety were also evaluated.
Results: the median percent changes in LPSI for pimecrolimus, clobetasol and calcipotriol groups were 51%, 56% and 59%, respectively (p>0.05). Pimecrolimus cream decreased cytokines levels and improved pathological features of psoriatic lesion. Mild skin burning was the most frequent adverse event reported by pimecrolimus (40%; p<0.05) versus 8% in clobetasol and 12% in the calcipotriol gr.
Conclusion: pimecrolimus cream demonstrated efficacy comparable with that of clobetasol and calcipotriol for the treatment of mild to moderate plaque psoriasis.
Downloads
Downloads
Published
Issue
Section
License
For all articles published in Journal of the Faculty of Medicine Baghdad, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY NC 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper rights.